![]() |
|
|
Vol. 301, Issue 1, 77-86, April 2002
Environmental Toxicology Center (S.G., A.A.E.) and Department of
Comparative Biosciences (S.G., M.R., A.A.E.), University of Wisconsin,
Madison, Wisconsin
Elevated glutathione (GSH) levels have been detected in many tumors
compared with the healthy, surrounding tissue. Often, this GSH
up-regulation is associated with drug resistance. The prodrugs
6-(2-acetylvinylthio)guanine (AVTG) and 6-(2-acetylvinylthio)purine (AVTP) contain a novel butenone moiety that allows the prodrugs to
react selectively with sulfhydryl nucleophiles to release the chemotherapeutic drug 6-thioguanine (6-TG) or 6-mercaptopurine (6-MP),
respectively. The cellular uptake and metabolism of
trans-AVTG in two human renal carcinoma cell lines that
were used as models were rapid and associated with depletion of
intracellular GSH. Formation of 6-TG from trans-AVTG
correlated positively with intracellular GSH concentrations, and was
significantly reduced by diethyl maleate pretreatment. Intracellular
concentrations of 6-TG after incubations with trans-AVTG
were significantly higher than the 6-TG concentrations obtained after
incubations with equimolar concentrations of 6-TG; thus, the prodrug
delivered more 6-TG to the cell than did 6-TG itself. Cytotoxicity
studies demonstrated that AVTG and AVTP had similar IC50
values that were comparable with those of 6-TG, but were significantly
lower than those of 6-MP. Furthermore, after in vivo treatment of mice
with the prodrugs, no reduction was observed in circulating white blood
cell counts, whereas white blood cell counts of mice treated with
equimolar or 60% lower doses of 6-TG were reduced by 50 to 60%.
Collectively, the results show that AVTG and AVTP are novel potential
chemotherapeutic agents that may target tumors with up-regulated levels
of GSH, and may exhibit less systemic toxicity than the parent thiopurines.
This article has been cited by other articles:
![]() |
C. L. Sprague, L. A. Phillips, K. M. Young, and A. A. Elfarra Species and Tissue Differences in the Toxicity of 3-Butene-1,2-diol in Male Sprague-Dawley Rats and B6C3F1 Mice Toxicol. Sci., July 1, 2004; 80(1): 3 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gunnarsdottir and A. A. Elfarra CYTOTOXICITY OF THE NOVEL GLUTATHIONE-ACTIVATED THIOPURINE PRODRUGS CIS-AVTP [CIS-6-(2-ACETYLVINYLTHIO)PURINE] AND TRANS-AVTG [TRANS-6-(2-ACETYLVINYLTHIO)GUANINE] RESULTS FROM THE NATIONAL CANCER INSTITUTE'S ANTICANCER DRUG SCREEN Drug Metab. Dispos., March 1, 2004; 32(3): 321 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gunnarsdottir and A. A. Elfarra DISTINCT TISSUE DISTRIBUTION OF METABOLITES OF THE NOVEL GLUTATHIONE-ACTIVATED THIOPURINE PRODRUGS CIS-6-(2-ACETYLVINYLTHIO)PURINE AND TRANS-6-(2-ACETYLVINYLTHIO)GUANINE AND 6-THIOGUANINE IN THE MOUSE Drug Metab. Dispos., June 1, 2003; 31(6): 718 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gunnarsdottir, M. Rucki, L. A. Phillips, K. M. Young, and A. A. Elfarra The Glutathione-activated Thiopurine Prodrugs trans-6-(2-Acetylvinylthio)guanine and cis-6-(2-Acetylvinylthio)purine Cause Less in Vivo Toxicity than 6-Thioguanine after Single- and Multiple-Dose Regimens Mol. Cancer Ther., November 1, 2002; 1(13): 1211 - 1220. [Abstract] [Full Text] [PDF] |
||||